Icon rejects Pfizer's Sandwich, but is hungry for 800 of its staff
This article was originally published in Scrip
In a Q2 earnings call with analysts, Icon CEO Peter Gray made it clear that the CRO will not take on Pfizer's facility in Sandwich, UK, as part of the preferred partnership deal it signed with the pharmaceutical giant at the end of May, that will see the research sponsor cull its strategic alliances from 17 to two.
You may also be interested in...
Perhaps only a man who inherited an enthusiasm for peptides could, without a trace of irony, cast diabetes drug development as the work of a pastry chef. But for David Solomon, the son of a peptide devotee, mixed metaphors and stretched comparisons are simply the spray thrown up by his unbridled enthusiasm for his chosen trade, that of basketball coach to GLP-1 receptor agonist developer Zealand Pharma.
"How the hell will Glaxo need you? You've only got a few people, they've got about 50,000!"